Mr. Greg Fenton reports

ZENTEK ANNOUNCES BOARD AND MANAGEMENT CHANGES

Zentek Ltd. has made the following changes to its board and management teams: (i) Dr. Francis Dube has resigned as chief operating officer of the company effective May 1, 2024, and (ii) Brian Bosse has resigned as a director of the company effective May 3, 2024, and has been appointed to the company's advisory board.

"Six years ago, we as shareholders of Zenyatta Ventures worked together to replace the board of directors and undertook a mission to create a better company. I had the privilege and honour to be the first chief executive officer and chairman of our company and I am incredibly grateful and want to say a huge thank you to all shareholders for the trust, friendships, and collaborations that we have shared over the last six years," said Mr. Dube. "My retirement is part of a process that started last fall when I began transitioning from the company and returned to my optometry practice to resume serving my local community as an optometrist. I will continue to help in a smaller role, but the company has built an incredible team under Greg's strong leadership. I firmly believe in the foundation we have collectively established, and I am thrilled and excited to witness the growth and commercialization of our technologies, including ZenGUARD and our aptamer platform."

"On behalf of all shareholders, I would like to thank Francis for his invaluable contribution to Zentek over the past six years. He was the catalyst that led the movement to create the change for what we have become today. I look forward to his continuing contributions to the company and I wish him all best in his future endeavours," commented Mr. Fenton.

"On behalf of the Zentek board of directors, I would like to thank Brian for his service to the board of directors and shareholders in general. We look forward to his continuing contribution as part of the Zentek advisory board," commented Eric Wallman, chairman of the Zentek board of directors.

In line with Mr. Bosse's appointment to the company's advisory committee, the company has granted to Mr. Bosse stock options to purchase 40,000 common shares of the company at a price of $1.42 per common share, which shall vest on May 3, 2025, and expire on May 3, 2027.

About Zentek Ltd.

Zentek is an ISO 13485:2016-certified intellectual property technology company focused on the research, development and commercialization of novel products seeking to give the company's commercial partners a competitive advantage by making their products better, safer and greener. Zentek's patented technology platform Zenguard is shown to have 99-per-cent anti-microbial activity and to significantly increase the bacterial and viral filtration efficiency of both surgical masks and HVAC (heating, ventilation and air conditioning) systems. Zentek's Zenguard production facility is located in Guelph, Ont. Zentek, through its wholly owned subsidiary Triera Biosciences, has a global exclusive licence to the aptamer-based platform technology developed by McMaster University, which is being jointly developed by Zentek and McMaster for both the diagnostic and therapeutic markets.

We seek Safe Harbor.